Even as the United States and China contest the boundaries of technological exchange, the pharmaceutical sector has emerged as an unlikely zone of continued cooperation. Reports that the U.S. Treasury is drafting rules to preserve American companies' ability to license drugs from Chinese firms sent biopharma stocks surging in Hong Kong, a market signal reflecting something deeper: that healing and commerce, when intertwined, can resist the gravitational pull of geopolitical fracture. The carve-out for weaponizable biotechnology suggests not an open door, but a carefully hinged one — wide enoug
U.S. signals openness to Chinese biopharma deals, lifting sector stocks
Investors now appear largely immune to geopolitical concerns
Mark
So the Treasury is basically saying they'll let American drug companies keep working with Chinese firms. Why does that matter enough to move stock prices?
Mimi
Because for the last couple of years, every policy signal from Washington toward China has been restrictive. AI, semiconductors, chips—all getting locked down. Biopharma investors have been waiting to see which side of that line they'd fall on. This says: you're allowed.
Luke
But the rules aren't final yet, right? And they're excluding anything related to pathogens or weaponizable biotech. How much of the actual deal flow does that carve-out affect?
Mimi
That's the thing—we don't know yet. The Treasury hasn't published specifics on what counts as weaponizable. But the market's reading this as a green light for the vast majority of oncology, immunology, and standard drug development work.
Mark
What's the actual volume we're talking about here?
Mimi
Eighty-one deals worth $110 billion in just the first half of 2026. Nearly half of all U.S. drug licensing deals in 2025 came from Chinese companies. This isn't a niche market.
Luke
And Pfizer's already in for $10.5 billion with Innovent on oncology programs. So the big players have already made their bets. This policy just removes the regulatory uncertainty hanging over them.
Mimi
Exactly. The market's been moving ahead of policy. Now policy is catching up.
Mark
Is there a reason biopharma gets treated differently than semiconductors or AI?
Mimi
China's genuinely competitive in drug development in ways it isn't in some other tech sectors. And there's less obvious dual-use risk with most cancer drugs than with advanced chips.
Luke
Though that's an assumption. We won't really know what the Treasury considers dual-use until they publish the rules. Right now we're trading on a report about a draft.
Mimi
True. But the direction is clear enough that investors are willing to act on it.
Il Polso
- Chinese biopharma stocks leapt 3–8% in a single session, with the Hang Seng Biotech Index climbing over 5%, as investors rushed to price in a policy signal that had not yet become policy.
- The tension is real: a U.S. government that has aggressively restricted Chinese access to AI chips and semiconductor technology is simultaneously moving to preserve a pharmaceutical pipeline worth tens of billions of dollars.
- The stakes are enormous — nearly half of all U.S. drug licensing deals in 2025 involved Chinese partners, and the first half of 2026 alone saw Chinese firms close a record 81 deals totaling $110 billion.
- The proposed rules would draw a firm line at dual-use biotechnology and pathogen-related research, threading a needle between national security and the practical reality that American pharma has grown deeply dependent on Chinese drug development.
- Nomura analysts note that investors now appear largely immune to geopolitical disruption in this sector, a confidence rooted in Chinese companies' proven capacity to produce novel, commercially viable drugs.
- If finalized, the Treasury rules would effectively codify existing market behavior, signaling that the China-U.S. biopharma bridge remains open — and that Beijing's five-year plan to globalize its pharmaceutical industry has found a receptive, if cautious, counterpart in Washington.
Even as the United States and China contest the boundaries of technological exchange, the pharmaceutical sector has emerged as an unlikely zone of continued cooperation. Reports that the U.S. Treasury is drafting rules to preserve American companies' ability to license drugs from Chinese firms sent biopharma stocks surging in Hong Kong, a market signal reflecting something deeper: that healing and commerce, when intertwined, can resist the gravitational pull of geopolitical fracture. The carve-out for weaponizable biotechnology suggests not an open door, but a carefully hinged one — wide enough for medicine, narrow enough for security.
Chinese biopharma stocks surged in Hong Kong on Monday after Reuters reported that the U.S. Treasury Department is drafting rules that would allow American pharmaceutical companies to continue licensing drugs from Chinese firms. Innovent Biologics, Akeso, and Sino Biopharmaceutical each climbed between 6% and 8%, while the Hang Seng Biotech Index rose more than 5% — a broad rally that reflected investor confidence in the policy's direction, even before any rules have been finalized.
The proposed framework would permit most drug licensing and investment deals to proceed, with one significant exception: transactions involving pathogens or biotechnology with potential weapons applications would remain off-limits. That carve-out distinguishes biopharma from sectors like artificial intelligence and semiconductors, where U.S. restrictions on Chinese firms have grown steadily tighter. In pharmaceuticals, the two countries appear to be moving in the opposite direction.
The numbers explain why. Nearly half of all U.S. drug licensing deals in 2025 involved Chinese companies, and in the first half of 2026 alone, Chinese firms completed a record 81 deals worth a combined $110 billion. Pfizer's $10.5 billion partnership with Innovent to co-develop twelve oncology programs is one prominent example of how deeply the two industries have become intertwined.
Nomura analysts noted that investors have grown largely unfazed by geopolitical turbulence in this sector, crediting Chinese companies' demonstrated strength in developing novel drugs. Beijing has also made pharmaceutical globalization a centerpiece of its 15th five-year plan, signaling long-term institutional commitment. If the Treasury rules are finalized as drafted, they would formalize what the market has already been practicing — keeping one consequential bridge between the United States and China firmly open for business.
Chinese biopharma stocks climbed sharply in Hong Kong trading on Monday, propelled by news that the U.S. Treasury Department is preparing rules that would permit American pharmaceutical companies to continue licensing drugs from Chinese firms. The sector's response was swift and broad: Innovent Biologics rose 6%, Akeso jumped 8%, CSPC Pharmaceutical Group gained more than 6%, HUTCHMED climbed 3%, and Sino Biopharmaceutical added 8%. The Hang Seng Biotech Index itself advanced more than 5%, signaling investor confidence across the space.
The catalyst came from a Reuters report citing people with knowledge of the process. According to those sources, the Treasury is drafting rules that would likely permit American pharmaceutical companies to invest in and license promising new drugs being developed by Chinese firms, with a notable carve-out: deals involving pathogens or biotechnology that could be weaponized would remain restricted. The rules have not yet been finalized and could still change, but the direction alone was enough to move markets.
This represents a meaningful divergence from how the U.S. has approached other technology sectors. While the government has tightened restrictions on Chinese companies in artificial intelligence and semiconductors, biopharma appears to be on a different trajectory. The distinction matters because it signals that not all technology sectors face the same level of scrutiny in U.S.-China relations.
The scale of China's pharmaceutical out-licensing business underscores why this policy signal carries weight. Nearly half of all U.S. drug licensing deals in 2025 involved Chinese companies, according to data from GlobalData. The momentum has only accelerated: in the first half of 2026 alone, Chinese firms completed a record 81 deals worth a combined $110 billion, according to figures cited by Nomura. These are not marginal transactions. Pfizer, for instance, announced a partnership worth up to $10.5 billion with Innovent in May to jointly research and develop twelve oncology programs.
What makes this moment notable is that China's out-licensing boom has persisted despite ongoing geopolitical tensions. Nomura analysts observed that investors now appear "largely immune" to intermittent geopolitical concerns affecting the sector, a shift they attribute to Chinese companies' demonstrated strength in developing novel drugs. The bank also noted that China has made globalization of its pharmaceutical and biotech companies a key objective under its 15th five-year plan, a multi-year commitment that suggests the government sees this sector as strategically important for economic growth.
With the Treasury rules likely to permit most drug licensing deals to proceed, Nomura expects China-U.S. out-licensing partnerships to "ride on a high tide" in the years ahead. The policy, if finalized as drafted, would essentially codify what the market has already been doing—allowing the flow of capital and intellectual property between American and Chinese pharmaceutical firms to continue, provided the deals do not involve dual-use biotechnology or pathogenic research. For investors in Chinese biopharma, the signal is that this particular bridge between the two countries remains open for business.
Citazioni salienti
Investors appear largely immune to intermittent geopolitical concerns around the sector, citing Chinese companies' strong value proposition in novel drug development.— Nomura analysts
China-U.S. out-licensing deals expected to ride on a high tide.— Nomura
Vuoi la storia completa?
Leggi l'originale su CNBC ↗
Economy & Finance